Haemonetics (HAE) FY2017 results: revenue $886 million, down 2.5% on the year
Haemonetics Corp. (HAE) reported revenue of $886 million for fiscal 2017, the year ended 1 April 2017, down 2.5% on the year before. Net income was -$26 million, and diluted earnings per share $-0.51. The figures are the company's own, from the 10-K it filed with the SEC on 22 May 2019.
Revenue
$886 million
-2.5% on the year
FY2010FY2017
Operating margin
-2.2%
-4.8% a year earlier
FY2010FY2017
Net income
-$26 million
FY2010FY2017
Diluted EPS
-$0.51
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
886
909
910
-2.5%
Cost of revenue
508
503
476
+0.9%
Gross profit
378
406
434
-6.8%
Gross margin
42.7%
44.7%
47.7%
Research and development
37.6
45.0
54.2
-16.5%
Selling, general and administrative
302
317
337
-4.9%
Operating income
-19.4
-43.9
40.5
Operating margin
-2.2%
-4.8%
4.5%
Pre-tax income
-27.5
-53.4
31.2
Income tax
-1.2
2.2
14.3
Effective tax rate
n/a
n/a
45.8%
Net income
-26.3
-55.6
16.9
Net margin
-3.0%
-6.1%
1.9%
Diluted EPS
-$0.51
-$1.09
$0.32
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
160
122
127
+31.1%
Capital expenditure
76.1
102
122
-25.7%
Free cash flow
83.6
19.5
5.0
+329.6%
Free cash flow margin
9.4%
2.1%
0.5%
Cash from investing
-73.3
-105
-122
Cash from financing
-60.4
-62.6
-33.2
Depreciation and amortisation
89.7
89.9
86.1
-0.2%
Share-based compensation
9.2
6.9
14.1
+31.7%
Buybacks
0.0
61.0
39.0
Diluted shares, weighted
52m
51m
52m
+1.2%
Shares outstanding at period end
52m
51m
52m
+2.6%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
740
722
826
+2.5%
Debt
316
408
430
-22.7%
Other liabilities
183
189
229
-3.1%
Total liabilities and equity
1,239
1,319
1,485
-6.1%
Fixed assets
324
338
322
-4.1%
Goodwill
211
268
334
-21.3%
Intangible assets
178
204
245
-13.2%
Cash and equivalents
140
115
161
+21.2%
Receivables
153
157
146
-2.8%
Inventory
177
187
211
-5.4%
Other assets
57.3
50.0
67.0
+14.7%
Total assets
1,239
1,319
1,485
-6.1%
10-K for the year ended 1 April 2017, filed 22 May 2019: the filing.